Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
2024 · Cancer Letters · 18 citations
https://doi.org/10.1016/j.canlet.2024.217124
M
Masaki Ishida
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
49
Papers
161
Citations
8
h-index
7
i10-index
Masaki Ishida is an academic researcher from Kyoto Prefectural University of Medicine. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Phagocytosis and Immune Regulation & Pancreatitis Pathology and Treatment. The author has an h-index of 8, co-authored 42 publications.
ORCID: 0000-0002-1890-7378Papers by this author
worksYAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
2024 · Clinical Cancer Research · 5 citations
https://doi.org/10.1158/1078-0432.ccr-24-1762
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study
2023 · JTO Clinical and Research Reports · 4 citations
https://doi.org/10.1016/j.jtocrr.2023.100493
Figure S5 from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.25124977
Data from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.c.7054186.v1
Figure S7 from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.25124971
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat